Ruixiang Xie

Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis

Lin Yang, Hui Wu, Brenda C. M. de Winter et al. · Cancer Chemotherapy and Pharmacology · 2020 · 24 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

Qiuling Zhao, Ruixiang Xie, Wanfu Zhong et al. · Cost Effectiveness and Resource Allocation · 2023 · 20 citations · Full text

<i>SLCO1B1</i> rs4149056 Genetic Polymorphism Predicting Methotrexate Toxicity in Chinese Patients with Non-Hodgkin Lymphoma

Lin Yang, Hui Wu, Teun van Gelder et al. · Pharmacogenomics · 2017 · 17 citations

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China

Ting Chen, Ruixiang Xie, Qiuling Zhao et al. · Frontiers in Oncology · 2022 · 10 citations · Full text